Frontiers in urology最新文献

{"title":"Care-associated adverse events related to the use of laser in urological interventions: the French experience.","authors":"Maher Abdessater, Frédéric Panthier, Philippe Michel, Vanessa Avrillon, Bertrand Pogu, Stéphane Bart","doi":"10.3389/fruro.2025.1507018","DOIUrl":"10.3389/fruro.2025.1507018","url":null,"abstract":"<p><strong>Introduction: </strong>The use of laser in urology is increasing, especially in renal stones and benign prostatic hypertrophy. Despite the interest in this technology on improving surgical management, several adverse events may result. This work collates French reports of care-associated adverse events (CAEs) resulting from lasers used in urological interventions.</p><p><strong>Materials and methods: </strong>This is a collection of CAEs between May 2016 and December 2023 declared by urologists involved in accreditation throughout France. These CAEs were classified according to five levels of severity. They have been described and classified according to the ALARM protocol. The statistics were mainly descriptive. Fisher's exact test and Student's <i>t</i>-test were used via the software R.</p><p><strong>Results: </strong>Between May 2016 and December 2023, between the 1,376 declared events, 149 laser-related CAEs were reported in urological interventions. Five CAEs (3.4%) were classified as grade 3, and six CAEs (4%) were classified as grade 4. All the other CAEs were between grades 1 and 2 with negligible consequences. The immediate reported causes of laser AEs were the clinical complexity of the case (7.38%), the technical gesture (14.1%), patient information (24.83%), material (38.25%), and medications (15.43%). Incidents caused by problems in material seem to be more frequent in younger patients (<i>p</i> < 0.001), healthier patients (ASA 1) (<i>p</i> = 0.003), risky situations (<i>p</i> < 0.001), and laser procedures (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>In France, 7.4% of CAEs related to the use of laser in urological surgery are of major to critical severity. Training teams on the use of laser generators and providing feedback on functional results and related specific morbidity seem necessary to guarantee the proper use of these technologies and the safety of staff and patients.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1507018"},"PeriodicalIF":1.1,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Immunotherapy in urologic malignancies.","authors":"Jayalekshmi Jayakumar, Arya Mariam Roy","doi":"10.3389/fruro.2025.1582134","DOIUrl":"10.3389/fruro.2025.1582134","url":null,"abstract":"","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1582134"},"PeriodicalIF":1.1,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Rising stars in urologic oncology: 2023.","authors":"Juan Gomez Rivas","doi":"10.3389/fruro.2025.1581141","DOIUrl":"https://doi.org/10.3389/fruro.2025.1581141","url":null,"abstract":"","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1581141"},"PeriodicalIF":1.1,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate cancer diagnosis and management: current practices in Africa a consultant-based survey.","authors":"Marcella Derboise Christelle Biyouma, Kaleab Habtemichael Gebreselassie, Saleh Abdelkerim Nedjim, Ouima Justin Dieudonné Ziba, Axel Stéphane Nwaha Makon, Anteneh Tadesse Kifle, Taofiq Olayinka Mohammed, Ayun Kotokai Cassell, Bencherki Youssef, Sissoko Idrissa, Orgeness Jasper Mbwambo, Mahamat Ali Mahamat, Rachid Aboutaieb, Tagang Titus Ngwa-Ebogo, Alain Khassim Ndoye, Emiola Oluwabunmi Olapade-Olaopa, Fru Fobuzshi Angwafo","doi":"10.3389/fruro.2025.1496951","DOIUrl":"10.3389/fruro.2025.1496951","url":null,"abstract":"<p><strong>Introduction: </strong>In Africa, prostate cancer poses significant diagnostic and treatment challenges due to limited access to diagnostic tools and healthcare resources. This survey aimed to assess current prostate biopsy practices, patient classification methods, and available therapeutic means among African urologists to propose strategies for improved screening, diagnosis, and management.</p><p><strong>Methods: </strong>A web-based self-administered questionnaire was distributed to urologists in 58 African centres, focusing on biopsy practices, cancer diagnosis, management, and treatment protocols. After pretesting and validation, data collection spanned six weeks, followed by duplicate elimination and arithmetical analysis, with results expressed in absolute, mean, or percentage values.</p><p><strong>Results: </strong>Feedback was received from 58 centres across diverse African regions, including Central, Southern, West, East Africa, and Madagascar, comprising general, private, and university hospitals. Prostate cancer emerged as the most frequent urological cancer in all regions studied. The assay for prostate-specific antigen (PSA) was available in nearly all centres. Biopsy techniques varied, with ultrasound-guided biopsies being the most common (30 centres), followed by digital-guided (20 centres) and MRI-guided biopsies (5 centres). One centre lacked the expertise to perform biopsies. Radiological workup availability was high, with CT available in 56 centres, MRI in 54, PET scans in 14, and scintigraphy in 29. Treatment capabilities varied, with 53.4% of centres able to perform radical prostatectomies, 86.2% offering radiotherapy, and 94.8% providing medical castration. Among the centres, 56 performed fewer than 5 radical prostatectomies per month, while only 2 centres performed between 5 and 10 per month.</p><p><strong>Conclusion: </strong>It is important to standardise prostate cancer diagnosis and treatment protocols across Africa while improving access to advanced diagnostic technologies and treatment facilities. Implementing these changes could enhance early detection, improve treatment outcomes, and reduce the burden of prostate cancer in Africa.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1496951"},"PeriodicalIF":1.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and treatment patterns of erectile dysfunction and hypogonadism in men with spina bifida: a retrospective study.","authors":"Nyemkuna Fortingo, Manpreet Sandhu, Garrick Greear, Tung-Chin Hsieh, Joshua Horns, Rupam Das, Jim Hotaling, Yahir Santiago-Lastra","doi":"10.3389/fruro.2025.1500839","DOIUrl":"10.3389/fruro.2025.1500839","url":null,"abstract":"<p><strong>Objectives: </strong>To characterize the estimated prevalence and treatment patterns of erectile dysfunction and hypogonadism in men with spina bifida through a large claims database.</p><p><strong>Methods: </strong>This retrospective claims study used the MarketScan^® databases from 2008 to 2017 to compare prevalence estimates for erectile dysfunction and hypogonadism in men with spina bifida to those in men without spina bifida and to describe treatment patterns in this cohort.</p><p><strong>Results: </strong>The estimated prevalence of erectile dysfunction and hypogonadism in men with spina bifida was 7.83% and 7.71%, respectively. Men with spina bifida exhibit high rates of smoking and metabolic comorbidities but are diagnosed less frequently with erectile dysfunction when controlling for age and metabolic comorbidities than men without spina bifida. Most men with spina bifida and erectile dysfunction (66.6%) or hypogonadism (77.4%) do not receive treatment. However, a diagnosis of spina bifida did not appear to affect the likelihood of treatment for either condition on multivariate analysis.</p><p><strong>Conclusions: </strong>Men with spina bifida are known to be at high risk for erectile dysfunction but may be diagnosed or treated less frequently than age and disease-matched men without spina bifida. Hypogonadism is diagnosed more frequently in men with spina bifida, which is a new finding that warrants further investigation. Most men with SB and either ED or HG do not receive treatment. The results suggest there is potential for improving care delivery for sexual health issues in men with spina bifida.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1500839"},"PeriodicalIF":1.1,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can handheld ultrasound probes reliably measure transabdominal prostate and bladder volumes? A prospective randomized point-of-care ultrasound study.","authors":"Henry C Wright, Dillon Corrigan, Smita De","doi":"10.3389/fruro.2024.1362734","DOIUrl":"10.3389/fruro.2024.1362734","url":null,"abstract":"<p><strong>Background: </strong>National guidelines recommend obtaining prostate gland volume (PGV) prior to benign prostate hyperplasia (BPH) surgery. Measurement of PGV with handheld ultrasound (HUS) probes shows promise.</p><p><strong>Objective: </strong>To compare the reliability of two HUS probes (Butterfly iQ and Clarius C3) to the BPH guideline-recommended imaging (GIm) for both prostate and bladder volumetrics.</p><p><strong>Methods: </strong>Male patients with GIm were randomized to undergo transabdominal HUS PGV with one of the two probes. A subset underwent voided volume measurements with one of the two HUS and a conventional bladder scanner (BS). The reliability of the volume measurements was assessed for each probe via intraclass correlation coefficients (ICCs). We utilized the following standard criteria: ICC < 0.5: poor reliability; 0.5 ≤ ICC < 0.75: moderate reliability; and ICC ≥ 0.75: good reliability.</p><p><strong>Results: </strong>A total of 78 men in the prostate arm (38 Butterfly, 40 Clarius) and 45 in the bladder arm (24 Butterfly, 21 Clarius) were randomized and included in this study. The mean prostate volume based on GIm was larger in the Clarius group (<i>p</i> = 0.044). Other baseline characteristics were similar between groups (<i>p</i> > 0.05). The ICCs were 0.78 (95% CI: 0.62, 0.88) and 0.71 (95% CI: 0.51, 0.83) for the Butterfly and Clarius probes, respectively. Regarding bladder volumetrics, the ICCs were 0.82 (95% CI: 0.19, 0.95), 0.72 (95% CI: 0.44, 0.88), and 0.69 (95% CI: 0.13, 0.87) for the Butterfly, Clarius, and bladder scanner, respectively.</p><p><strong>Conclusions: </strong>The Butterfly iQ demonstrated good reliability for PGV and voided volume measurements, in comparison to moderate reliability for Clarius C3.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"4 ","pages":"1362734"},"PeriodicalIF":1.1,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary large cell neuroendocrine carcinoma of the urethra: a case report.","authors":"Jianbai Chen, Xiaorong Mou, Zhiming Zhang, Zhiyong Nie, Jianxin Qiu","doi":"10.3389/fruro.2025.1440538","DOIUrl":"10.3389/fruro.2025.1440538","url":null,"abstract":"<p><strong>Background: </strong>Primary neuroendocrine carcinoma of the urethra is a very uncommon malignant tumor, and no reports have been made about large cell neuroendocrine carcinoma (LCNEC) in the past.</p><p><strong>Case description: </strong>A 43-year-old non-smoking female patient presented with symptoms of dysuria and urination-related pain at TangDu Hospital in April 2022. A biopsy subsequently confirmed the diagnosis of primary urethral LCNEC. Following radical resection, the patient exhibited abnormal lymph node enlargement in the first month and pelvic metastases in the fourth month. Ultimately, the patient succumbed to the disease 486 days after the radical resection, attributed to widespread tumor metastases and concurrent multi-organ failure. The final pathological examination confirmed the presence of a high-grade LCNEC.</p><p><strong>Conclusion: </strong>The occurrence of primary LCNEC in the urethra is exceptionally uncommon. This particular instance was notable for its aggressive progression and unfavorable prognosis. Historically, there have been no prior documented instances of primary pure LCNEC in the urethra. It is imperative to emphasize that early identification and intervention for LCNEC could potentially offer patients a more favorable survival outcome.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1440538"},"PeriodicalIF":1.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Multidisciplinary management of urological malignancies in the era of precision medicine: integration of advances in technology and cancer care.","authors":"Lilia Bardoscia, Beatrice Detti, Angela Sardaro","doi":"10.3389/fruro.2024.1518410","DOIUrl":"10.3389/fruro.2024.1518410","url":null,"abstract":"","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"4 ","pages":"1518410"},"PeriodicalIF":1.1,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anogenital distance in the etiology of chronic prostatitis: does it lead to novel surgical treatments?","authors":"Ayhan Verit, Fatma Ferda Verit","doi":"10.3389/fruro.2024.1418007","DOIUrl":"10.3389/fruro.2024.1418007","url":null,"abstract":"","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"4 ","pages":"1418007"},"PeriodicalIF":1.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Giant prostatic hyperplasia in a 54-years old patient treated by prostate artery embolization: case report.","authors":"Nicolas Villard, Georgia Tsoumakidou, Paul C Moldovan, Rémy Rosset, Olivier Rouvière, Hakim Fassi-Fehri, Gaële Pagnoux","doi":"10.3389/fruro.2024.1446650","DOIUrl":"10.3389/fruro.2024.1446650","url":null,"abstract":"<p><p>Giant prostatic hyperplasia (GPH) is defined as benign prostate hyperplasia (BPH) of more than 200 ml. It is a challenging condition because transurethral resection is classically indicated for prostate volume less than 80 ml and open adenectomy remains the gold standard therapy for GPH. Herein, we present the case of a 54-years old male with giant prostatic hyperplasia (total prostate volume of 265 ml) causing lower urinary tract symptoms (LUTS) and recurrent episodes of acute urinary retention. The patient refused the surgical adenomectomy and underwent bilateral prostate arteries embolization (PAE). Post embolization period was uneventful. Total prostate volume decreased progressively and LUTS disappeared. At more than 5 years follow-up the patient remains still asymptomatic, despite the discrete regrowth of the prostate detected on imaging. This case report suggests that PEA may be a good alternative to open surgery for patients with symptomatic GPH.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"4 ","pages":"1446650"},"PeriodicalIF":1.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}